沈阳兴齐眼药股份有限公司 2024 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）2024年半年度权益分派方 案已获2024年9月13日召开的2024年第二次临时股东大会审议通过，现将权益分 派事宜公告如下： 一、股东大会审议通过权益分派分配方案情况 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-046 1、公司 2024 年第二次临时股东大会审议通过的 2024 年半年度权益分派方 案为：以现有总股本 174,424,871 股为基数，向全体股东每 10 股派发现金红利 5.00 元（含税），共分配现金红利 87,212,435.50 元（含税）；不以公积金转增股 本，不送红股；剩余未分配利润结转未来分配。 若在分配方案实施前，公司总股本由于股份回购注销、增发新股、股权激励 行权、可转债转股等原因发生变动的，将按照现金分红总额固定不变的原则，相 应调整分配。 2、自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与 2024 年第二次临时股东大 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-045 沈阳兴齐眼药股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 2、现场会议时间：2024年9月13日（星期五）下午14:30。 3、网络投票时间：2024年9月13日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为2024年9月13日9:15—9:25，9:30—11:30和13:00— 15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为2024年9月13 日9:15至15:00期间的任意时间。 4、现场会议召开地点：沈阳市浑南区泗水街68号，沈阳兴齐眼药股份有限 公司E1号楼，二楼多功能厅。 5、会议召集人：2024年8月29日，公司董事会以公告方式向全体股东发出2024 年第二次临时股东大会的会议通知。 6、会议主持 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于沈阳兴齐眼药股份有限公司 2024 年第二次临时股东大会的法律意见书 致：沈阳兴齐眼药股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称 "《公司法》"）以及中国证券监督管理委员会颁布的《上市公司股东大会规 则》（以下简称"《股东大会规则》"）的规定，北京市竞天公诚律师事务所 （以下简称"本所"）指派律师出席了沈阳兴齐眼药股份有限公司（以下简称 "公司"）2024年第二次临时股东大会（以下简称"本次股东大会"），并就 本次股东大会的有关事宜出具本法律意见书。 本所在此同意，公司可以将本法律意见书作为本次股东大会公告的法定文 件，随其他公告文件一并提交深圳证券交易所予以审核公告。 本所律师根据《股东大会规则》第五条的要求，按照律师行业公认的业务 标准、道德规范和勤勉尽责精神，对本次股东大会召集和召开的有关事实及公 司提供的文件进行了核查和验证，现出具法律意见如下： 一、本次股东大会的召集、召开程序 1、本次 ...

海通证券股份有限公司关于沈阳兴齐眼药股份有限公司 2024 年半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：兴齐眼药 | | --- | --- | | 保荐代表人姓名：石迪 | 联系电话：021-23187088 | | 保荐代表人姓名：王显 | 联系电话：021-23185968 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2、督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、募 | 是 | | 集资金管理制度、内控制度、内部审计制度、 | | | 关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-044 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-22031滴眼液于 近日完成了"评估SQ-22031滴眼液在健康受试者中单次/多次给药的安全性、耐 受性和药代动力学的单中心、随机、双盲、安慰剂对照I期临床试验"首例受试 者入组，正式进入该临床试验。现将有关内容公告如下： 一、基本情况 药物名称：SQ-22031 滴眼液 注册分类：治疗用生物制品 1 类 剂型：滴眼剂 适应症：神经营养性角膜炎 临床试验批准通知书编号：2024LP01687、2024LP01688、2024LP01689、 2024LP01690 沈阳兴齐眼药股份有限公司 关于 SQ-22031 滴眼液Ⅰ期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 和药代动力学特征。 三、同类药品的情况 截至本公告披露日，经查询国家药品监督管理局网站，尚无同品种药品批准 上市。 四、对公司的影响 临床试验分期：Ⅰ期 申办方：沈阳兴齐眼药股份有限公司 二、临床试验相关情况 神经营养性角膜炎（Neu ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 122.50 CNY [4][2]. Core Insights - The company reported significant revenue growth, achieving 892 million CNY in revenue for the first half of 2024, a year-on-year increase of 30.10%, and a net profit of 169 million CNY, up 92.95% year-on-year [1]. - The eye drop segment saw accelerated revenue growth, particularly due to the launch of low-concentration atropine, which contributed to a 62.97% increase in revenue for this product line [1]. - The company has a rich product pipeline with 58 approved ophthalmic drugs, including 35 listed in the medical insurance directory, which supports its revenue base [1]. Financial Performance Summary - For the first half of 2024, the company achieved a gross profit margin of 80.3%, with net profit margins projected to reach 19.7% by 2024 [2][12]. - The forecasted net profits for 2024, 2025, and 2026 are 501 million CNY, 734 million CNY, and 970 million CNY respectively, indicating strong growth potential [2][12]. - The company's earnings per share (EPS) is projected to be 2.87 CNY for 2024, increasing to 5.56 CNY by 2026 [2][12].

证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 投资者关系活动记录表 编号：2024-004 | --- | --- | --- | --- | --- | --- | |---------------------------|-------|--------------------------------|-------------|------------------------------------------------|----------------------------------------------------------------| | | □ | 特定对象调研 □ | | 分析师会议 | | | 投资者关系 | □ | 媒体采访 □ | | 业绩说明会 | | | 活动类别 | □ | 新闻发布会 | □ | 路演活动 | | | | □ | 现场参观 √ | | 其他（电话会议） | | | 参与单位名称 及人员姓名 | | 详见附件：参加交流活动人员名单 | | | | | 时间 2024 | | 年 08 月 29 日 | 15:00-15:55 | ...

Investment Rating - The report maintains a "Buy-A" investment rating for the company [5][6]. Core Views - The company achieved rapid growth in H1 2024, with revenue reaching 892 million yuan, a year-on-year increase of 30.10%, and a net profit of 169 million yuan, up 92.95% year-on-year [2][3]. - The core product, 0.01% atropine sulfate eye drops, has been approved and is expected to see sustained sales growth due to a large potential market among children with myopia [4][5]. - The company is actively conducting clinical trials for 0.02% and 0.04% atropine sulfate eye drops, which will help meet the treatment needs of patients with varying degrees of myopia [4]. Financial Summary - For H1 2024, the revenue breakdown includes gel/eye ointment at 176 million yuan (-0.58%), eye drops at 512 million yuan (+62.97%), and medical services at 164 million yuan (+5.44%) [3]. - The projected net profits for 2024 to 2026 are estimated at 500 million yuan, 644 million yuan, and 760 million yuan respectively, with an expected EPS of 2.86 yuan per share for 2024 [5][9]. - The company's total market capitalization is approximately 17.44 billion yuan, with a circulating market value of about 13.40 billion yuan [6]. Price Target - The report sets a 6-month target price of 114.40 yuan per share, based on a 40x PE ratio [5][6].

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-042 沈阳兴齐眼药股份有限公司 关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及 《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的相关规 定，沈阳兴齐眼药股份有限公司（以下简称"公司"、"本公司"）就 2024 年半年 度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2021]1343 号文批准，公司向特定对 象发行人民币普通股5,763,282股，募集资金总额为人民币599,669,492.10元， 实际收到募集资金为人民币 581,870,425.73 元（已扣除承销费用（含增值税））。 上述募集资 ...

Financial Performance - The company's operating revenue for the current period is ¥891,799,280.33, representing a 30.10% increase compared to ¥685,470,748.67 in the same period last year[38]. - Net profit attributable to shareholders for the current period is ¥169,320,445.67, a significant increase of 92.95% from ¥87,754,641.26 in the previous year[38]. - The net profit after deducting non-recurring gains and losses is ¥168,612,418.22, reflecting a 96.55% increase compared to ¥85,785,478.10 last year[38]. - Cash generated from operating activities is ¥186,739,212.34, up 79.76% from ¥103,883,336.66 in the same period last year[38]. - Basic and diluted earnings per share are both ¥0.99, marking a 90.20% increase from ¥0.51 in the previous year[38]. - The company's total assets at the end of the current period are ¥2,082,705,443.09, a 2.91% increase from ¥2,023,844,736.22 at the end of the previous year[38]. - Net assets attributable to shareholders decreased by 11.00% to ¥1,504,080,488.86 from ¥1,689,920,857.47 at the end of the previous year[38]. - The company achieved a net profit attributable to ordinary shareholders of 169,320,445.67 CNY for the first half of 2024, with a cumulative distributable net profit of 409,936,982.97 CNY[108]. - The company reported a total revenue of 1,734.76 million RMB for the first half of 2024, reflecting a growth of 12.5% compared to the same period last year[158]. Research and Development - The company plans to increase R&D investment and expand its ophthalmic product line to mitigate risks from intensified industry competition and the emergence of alternative drugs[7]. - The company is committed to advancing key R&D projects and expanding its R&D pipeline to manage risks associated with unmet project expectations[9]. - The company is focused on developing new ophthalmic drugs and expanding its product line[29]. - The company’s R&D investment amounted to CNY 92.90 million, reflecting a 7.88% increase from CNY 86.11 million in the previous year, indicating a continued focus on innovation[71]. - The company is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and user experience[192]. - The company has established a comprehensive eye drug product system, focusing on professional and diversified development in the ophthalmic field[52]. Market Strategy and Expansion - The company aims to enhance its market share and sales coverage to address potential risks of slowing performance and unmet expectations due to intensified market competition[8]. - The company has formed stable partnerships with major pharmaceutical distributors and e-commerce platforms to enhance sales growth across various channels[60]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[121]. - Market expansion efforts include entering two new provinces, which are expected to contribute an additional 150 million yuan in revenue by year-end[192]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for this purpose[192]. Compliance and Risk Management - The company is focused on maintaining compliance and improving operational strategies to navigate the evolving regulatory landscape in the pharmaceutical industry[6]. - The company acknowledges the risks associated with rapid scale expansion and plans to enhance management training and recruit new personnel to address these challenges[13]. - The company recognizes the ongoing risks from industry policy adjustments and drug price fluctuations, and it is enhancing its response capabilities to these changes[5]. - The company is implementing measures to mitigate risks associated with rising costs and quality control challenges in the pharmaceutical industry[94]. - The company is facing risks related to industry policy adjustments and intensified competition, prompting a need for strategic responses[93]. Environmental Responsibility - The company has applied for a pollutant discharge permit valid from July 28, 2023, to July 27, 2028[118]. - The company reported a total wastewater discharge of 319 tons, with a COD concentration of 0.403 g/L[118]. - The company has completed the environmental impact assessment for the R&D center construction project in the first half of 2024[118]. - The company upgraded its wastewater treatment plant in 2023, increasing the daily processing capacity to 480m³/day[119]. - The company conducts manual monitoring of boiler emissions once a month to ensure compliance with environmental standards[120]. Shareholder Relations and Dividends - The company reported a cash dividend of 5 RMB per 10 shares (including tax) based on 174,424,871 shares, with no bonus shares issued[15]. - The company plans to distribute a cash dividend of 5.00 CNY per 10 shares (including tax), totaling 87,212,435.50 CNY, based on a total share capital of 174,424,871 shares[108]. - The total cash dividend distributed since the company's listing has reached 732 million CNY, with 11 cash dividend distributions implemented[100]. - The company maintains a profit distribution policy that emphasizes continuity and stability, ensuring that investors share in the company's development achievements[100]. - The company has established multiple channels for investor relations management, including a dedicated investor hotline and a WeChat public account[101]. Corporate Governance - The company held its first extraordinary general meeting on January 5, 2024, approving the election of the fifth board of directors and supervisory board members[149]. - The company’s board of directors and supervisory board elections were conducted in accordance with the relevant regulations[149]. - The company has not engaged in any major related party transactions during the reporting period[137]. - The semi-annual financial report has not been audited, indicating that the figures presented are preliminary[169].